These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17700603)

  • 41. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.
    Zappasodi P; Nosari AM; Astori C; Ciapanna D; Bonfichi M; Varettoni M; Mangiacavalli S; Morra E; Lazzarino M; Corso A
    Transfusion; 2008 May; 48(5):857-60. PubMed ID: 18248573
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sequential high-dose chemotherapy with autologous stem cell support in patients with limited-stage small cell lung cancer.
    Ziske C; Gorschlüter M; Mey U; Offergeld R; Glasmacher A; Schmidt-Wolf IG
    Anticancer Res; 2002; 22(6B):3723-6. PubMed ID: 12552983
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
    Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
    Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).
    Nishimura Y; Nakagawa K; Takeda K; Tanaka M; Segawa Y; Tsujino K; Negoro S; Fuwa N; Hida T; Kawahara M; Katakami N; Hirokawa K; Yamamoto N; Fukuoka M; Ariyoshi Y
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):786-92. PubMed ID: 17512126
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.
    Stemmler HJ; Salat C; Lindhofer H; Menzel H; Untch M; Kahlert S; Konecny G; Sauer H; Ledderose G; Heinemann V; Kolb HJ
    Anticancer Res; 2005; 25(4):3047-54. PubMed ID: 16080564
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
    Vahdat LT; Balmaceda C; Papadopoulos K; Frederick D; Donovan D; Sharpe E; Kaufman E; Savage D; Tiersten A; Nichols G; Haythe J; Troxel A; Antman K; Hesdorffer CS
    Bone Marrow Transplant; 2002 Aug; 30(3):149-55. PubMed ID: 12189532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: preliminary results.
    Ohguri T; Imada H; Narisada H; Yahara K; Morioka T; Nakano K; Miyaguni Y; Korogi Y
    Int J Hyperthermia; 2009 Mar; 25(2):160-7. PubMed ID: 19337916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J
    Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
    Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
    Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer.
    Chikamori K; Kishino D; Takigawa N; Hotta K; Nogami N; Kamei H; Kuyama S; Gemba K; Takemoto M; Kanazawa S; Ueoka H; Segawa Y; Takata S; Tabata M; Kiura K; Tanimoto M;
    Lung Cancer; 2009 Jul; 65(1):74-9. PubMed ID: 19056143
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
    J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
    Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
    Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer.
    Takayama K; Kawasaki M; Ninomiya K; Motohiro A; Fujita M; Watanabe K; Kajiki A; Iwami F; Miyazaki N; Izumi M; Hara N; Nakanishi Y;
    Respirology; 2008 Jan; 13(1):103-7. PubMed ID: 18197918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
    Yanagitani N; Tsuchiya S; Kaira K; Sunaga N; Tsuchiya Y; Sato K; Watanabe S; Nomura S; Sakai S; Saito R; Mori M
    Am J Clin Oncol; 2007 Oct; 30(5):487-91. PubMed ID: 17921708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [CBDCA, etoposide and epirubicin high-dose combination chemotherapy supported by peripheral blood stem cell transplantation (PBSCT) in metastatic breast cancer].
    Suwata J; Takada S; Murata N; Ishizuka N; Idezuki Y; Kobayashi M
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):83-8. PubMed ID: 9987502
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose chemotherapy in small-cell lung cancer.
    Pasini F; Durante E; De Manzoni D; Rosti G; Pelosi G
    Anticancer Res; 2002; 22(6B):3465-72. PubMed ID: 12552940
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
    Kondagunta GV; Bacik J; Sheinfeld J; Bajorin D; Bains M; Reich L; Deluca J; Budnick A; Ishill N; Mazumdar M; Bosl GJ; Motzer RJ
    J Clin Oncol; 2007 Jan; 25(1):85-90. PubMed ID: 17194908
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel.
    Yamamoto H; Sekine I; Yamada K; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
    Oncology; 2008; 75(3-4):169-74. PubMed ID: 18827494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
    Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M
    Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
    Fornier MN; Seidman AD; Lake D; D'Andrea G; Bromberg J; Robson M; Van Poznak C; Panageas KS; Atienza M; Norton L; Hudis C
    Clin Cancer Res; 2007 Jan; 13(1):223-7. PubMed ID: 17200358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.